6125 Topoisomerase-1 (Topo1) as a predictive and prognostic factor in colorectal cancer chemotherapy
Susan D. Richman(University of Leeds), Michel Seymour(University of Leeds), Richard Kaplan(University College London), Philip Quirke(University of Leeds), Harpreet Wasan(Hammersmith Hospital), Craig Daly, R.E. Langley, M.K.B. Parmar, Lindsay C Thompson(MRC Clinical Trials Unit at UCL)
Cited by 1
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k